H. Lundbeck A/S

H. Lundbeck A/S researches, develops, manufactures, and commercializes pharmaceuticals for psychiatric and neurological disorders in Europe, the United States, and internationally. Its marketed products include Abilify Maintena/Abilify Asimtufii for schizophrenia and bipolar I disorder in adults, Brintellix/Trintellix for depressive disorders, Rexulti/Rxulti for major depressive disorder and schizophrenia, Vyepti for migraine prevention, and Cipralex/Lexapro for depression. The company also provides Northera for symptomatic neurogenic orthostatic hypotension, Onfi for epilepsy, Sabril for refractory complex partial seizures and infantile spasms, Ebixa for dementia, Azilect for Parkinson's disease, Xenazine for chorea, Deanxit for depression, Cipramil for depression and anxiety, and Cisordinol for psychosis. Its development pipeline includes Eptinezumab for migraine prevention and in phase 3 for cluster headache, Lu AG09222 in phase 2 for migraine prevention, Lu AG13909 in phase 1 for neurohormonal dysfunctions, Brexpiprazole for post-traumatic stress disorder, Lu AF28996 in phase 1 for Parkinson's disease, the MAGLi program in phase 1 for neurology, Bexicaserin in phase 3 for developmental and epileptic encephalopathies, Amlenetug in phase 3 for synucleinopathies, and Lu AG22515 in phase 1 for neurology. Lundbeck has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.